Figure 3

Sorafenib treatment inhibits the phosphorylation of CSE1L and ERK1/2. a Sorafenib treatment inhibited the phosphorylation of ERK1/2 and CSE1L. The levels of hyper-phosphorylated CSE1L, hypo-phosphorylated CSE1L, and phospho-ERK1/2 in HT-29 colorectal cancer cells treated with or without 6 μM sorafenib for 24 h were subjected to immunoblotting with anti-CSE1L (clone 3D8), anti-phospho-CSE1L, and anti-phospho-ERK1/2 antibodies. β-actin levels were assayed as a control. Each immunoblot was repeated at least three times and showed similar results. The data shown here are the representative immunoblots. b The cell numbers of HT-29 colorectal cancer cells treated with or without 6 μM sorafenib for 96 h were counted using trypan blue exclusion assays. The graph summarizes the results of three independent assays.